Neurological conditions such as stroke or spinal cord injury often result in the loss of motor function in one or both hands. Occupational therapy can help with restoration to a meaningful degree, but is only effective with a significant number of repetitive hand exercises. This means patients who are unable to meet the cost of travel requirements lack access to consistent treatment.
While rehabilitation robotic devices are available, conventional models are typically powered by stiff electromechanical motors that only offer the fingers one degree of freedom. As a result, training may feel unnatural and uncomfortable.
To address this problem, Roceso Technologies developed Esoglove, a soft robotic hand rehabilitation system. Designed and manufactured in Singapore, it comprises two components: a lightweight, flexible glove that does not hyperextend fingers and supports a natural grasp during flexion; and a small machine equipped with sensors that trigger neuroplasticity by providing biofeedback. Over 50 countries have approved it for medical use.
Jane Wang, CEO and Co-founder of Roceso Technologies, met her co-founders while pursuing a master’s degree in Intellectual Property and Technology Management at NUS. The trio founded the company in 2016 out of a shared interest in healthcare and medtech.
It is important to Wang that innovation remains constant in spite of the ground they have covered, and is why, among other triumphs, Esoglove has been able to octuple of exercises offered over the last five years.
However, developing a medical device in a market with a high barrier to entry comes with several challenges. For one, the supply chain is complex. Besides traditional electronics components, Esoglove also requires special fabrics, tubing, sensors, and production partners for its entire manufacturing process.
Another challenge is the navigation of a new business model.
“A new medical innovation must overcome a lack of reimbursement when first introduced, which means justifying the benefits we can offer our customers so they will be willing to pay.”
Jane Wang on one big challenge in medtech
The price of a basic Esoglove model currently starts at $20,000. Recognising that it is a sum few can afford, Roceso Technologies introduced a rental programme that starts from $520 a month for a minimum of three months. If a patient is deemed suitable for the system after a trial period, the company installs it at their home, provides training, and prescribes a treatment plan on its cloud-based remote therapeutic system. Monthly visitations are carried out to evaluate progress.
Roceso Technologies had spent its earlier years exploring foreign markets, but switched its focus back to Singapore when it observed heightened interest and acceptance. It helps that the local market boasts strong purchasing power, a high literacy rate, and easy access to customers, Wang adds.
According to her, Esoglove has not only installed in many major local public hospitals and rehabilitation centres, but also been gaining traction in the nursing home sector.
While support from the government in the form of grants, fair subsidies, and overseas mission trips, Wang hopes that the industry receives further support. “In terms of tech startups and venture capital, Singapore is still relatively young. Both investors and talent need more confidence in the space.”
Her advice for those looking to join the industry is to brace for a bumpy but fulfilling ride. “Be patient and prepared for a long, fun journey.”
Art direction: Ed Harland
Photography: Cher Him
Hair & makeup: Wee Ming using Chanel beauty & Schwarzkopf Professional
